Images List Premium Download Classic

Proliferative

Proliferative-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Gene composition for detecting cell proliferative abnormality or grading disease degree and use thereof
Biochain (beijing) Science & Technology, Inc.
January 18, 2018 - N°20180016639

The present invention provides a composition, a kit and the use thereof, as well as the method for detecting the cell proliferative abnormality in individuals or grading the disease degree in the individuals. The composition comprises nucleic acids for detecting the methylation level within at least one target region of a gene and the fragment thereof.
NEW Autotaxin inhibitory compounds
Cancer Research Technology Limited
January 18, 2018 - N°20180016274

The present invention relates to compounds of formula i, wherein a1, a2, a3, r1, r2, r3, r4, r5, r6, l, ar and q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (atx) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and ...
NEW 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg
Cancer Research Technology Limited
January 18, 2018 - N°20180016242

The present invention relates to compounds of formula i that function as inhibitors of parg (poly adp-ribose glycohydrolase) enzyme activity wherein r1a, r1b, r1c, r1d, r1e, w, x1, x2, x3, x4, x5, x6, x7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical ...
NEW Proliferative Patent Pack
Download 369+ patent application PDFs
Proliferative Patent Applications
Download 369+ Proliferative-related PDFs
For professional research & prior art discovery
inventor
  • 369+ full patent PDF documents of Proliferative-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Anti-dll3 antibody drug conjugates and methods of use
Abbvie Stemcentrx Llc
January 18, 2018 - N°20180015178

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
NEW Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
Bayer Pharma Aktiengesellschaft
January 18, 2018 - N°20180015176

The present application relates to novel binder drug conjugates (adcs), to active metabolites of these adcs, to processes for preparing these adcs, to the use of these adcs for the treatment and/or prophylaxis of diseases and to the use of these adcs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders ...
NEW Highly active anti-neoplastic and anti-proliferative agents
G1 Therapeutics, Inc.
January 18, 2018 - N°20180015096

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
NEW Proliferative Patent Pack
Download 369+ patent application PDFs
Proliferative Patent Applications
Download 369+ Proliferative-related PDFs
For professional research & prior art discovery
inventor
  • 369+ full patent PDF documents of Proliferative-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Crenolanib for treating flt3 mutated proliferative disorders
Arog Pharmaceuticals, Inc.
January 18, 2018 - N°20180015081

The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of flt3 mutated proliferative disorders driven by constitutively activated mutant flt3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
Methods for identifying, diagnosing, and predicting survival of lymphomas
Queen Mary And Westfield College, University Of London
January 11, 2018 - N°20180011106

Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, ...
Recurrent gene fusions in cutaneous cd30-positive lymphoproliferative disorders
The Regents Of The University Of Michigan
January 11, 2018 - N°20180010196

Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e. G., recurrent translocations involving tyk2) as diagnostic markers and clinical targets for cutaneous cd30-positive lymphoproliferative disorders (e. G., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).
Furoquinolinediones as inhibitors of tdp2
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
January 11, 2018 - N°20180009822

Compounds of formula i and the pharmaceutically acceptable salts thereof are disclosed formula i. The variables x1, x2, and r1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of formula i and methods of treatment comprising administering compounds of formula i are also disclosed.
Resorcinol derivative as hsp90 inhibitor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
January 11, 2018 - N°20180009794

The present invention relates to a compound represented by formula (i) of a resorcinol derivative as an hsp90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein hsp90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present ...
Methods to induce targeted protein degradation through bifunctional molecules
Dana-farber Cancer Institute, Inc.
January 11, 2018 - N°20180009779

The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative ...
Multi-tyrosine kinase inhibitors derivatives and methods of use
Ontogenesis, Llc
January 11, 2018 - N°20180009758

The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with ...
Proliferative Patent Pack
Download 369+ patent application PDFs
Proliferative Patent Applications
Download 369+ Proliferative-related PDFs
For professional research & prior art discovery
inventor
  • 369+ full patent PDF documents of Proliferative-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof
Guangzhou Institutes Of Biomediciene And Health, Chinese Academy Of Sciences
January 11, 2018 - N°20180008574

The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof. The compound and pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate, and solvate thereof can effectively inhibit the bet bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell proliferative disorders, ...
Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
January 04, 2018 - N°20180007043

Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.
Cytotoxic benzodiazepine derivatives
Immunogen, Inc.
January 04, 2018 - N°20180002440

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (i)-(vii). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds ...
Methods of using interleukin-10 for treating diseases and disorders
Armo Biosciences, Inc.
January 04, 2018 - N°20180002434

Methods of treating subjects having a proliferative disease, disorder, or condition, including cancer, via the administration of an il-10 agent, including pegylated il-10, in combination with an antibody capable of inducing anti-body-dependent cell-mediated cytotoxicity, are provided.
Cd33 specific chimeric antigen receptors
Intrexon Corporation
January 04, 2018 - N°20180002397

Provided herein are chimeric antigen receptors (cars) for cancer therapy, and more particularly, cars containing a scfv from a cd33 monoclonal antibody. Provided are immune effector cells containing such cars, and methods of treating proliferative disorders such as acute myeloid leukemia (aml), and relapsed or refractory aml.
Serine/threonine kinase inhibitors
Genentech, Inc.
January 04, 2018 - N°20180000833

Compounds having the formula i wherein r1, x1, x2, x3 and x4 as defined herein are inhibitors of erk kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
Novel compound useful for the treatment of degenerative and inflammatory diseases
Galapagos Nv
January 04, 2018 - N°20180000831

A novel compound able to inhibit jak is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/...
Compositions of fatostatin based heterocyclic compounds and uses thereof
Fgh Biotech, Inc.
January 04, 2018 - N°20180000801

The present invention relates to compounds, pharmaceutical compositions and formulations that have a structure (i). The compounds comprise a heterocyclic ring where w, x, y, and z generally and independently are s, n or c with the proviso that at least 2 of these positions in the ring are other than carbon. A pyridine or a substituted pyridine a ring and ...
Loading